884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

Published 2019 View Full Article

Authors

Keywords

Journal

Open Forum Infectious Diseases

Volume 6, Issue Supplement_2, Pages S20-S20

Publisher

Oxford University Press (OUP)

Online

2019-10-24

DOI

10.1093/ofid/ofz359.043

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

Open Forum Infectious Diseases

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Discover Peeref hubs

Ask a Question. Answer a Question.